Alfuzosin Versus Placebo in Acute Urinary Retention (ALF-RIK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00453908|
Recruitment Status : Terminated (The study was early terminated due to slow and difficult recruitment)
First Posted : March 29, 2007
Last Update Posted : August 20, 2007
The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with Clean Self-Catheterization.
Furthermore is investigated the safety of the medical treatment and self-catheterization.
|Condition or disease||Intervention/treatment||Phase|
|Urinary Retention||Drug: Alfuzosin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Does Alfuzosin OD vs. Placebo in Male Patients Facilitate Spontaneous Voiding During Clean Intermittent Self-Catheterization Following Acute Urinary Retention?|
|Study Start Date :||May 2004|
- Number of patients with satisfying spontaneous voiding after 14 days measured by bladder scan at day 14.
- Number of days until termination of self catheterization
- Number of patients with urinary infection requiring treatment
- Pressure of voiding, volume of voiding, residual urine after voiding, measured by urine culture and bladder scan at day 14.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00453908
|Study Director:||Henning Andersen, MD||Sanofi|